Merz Aesthetics® Launches Ultherapy PRIME® in the EMEA Region at the 2025 IMCAS World Congress

23.1.2025 09:00:00 CET | Business Wire | Press release

New Data is presented in the field of regenerative aesthetics

Merz Aesthetics launches Ultherapy PRIME^® in Europe, Middle East and Africa, an evolution of the non-invasive skin lifting Ultherapy^® and presents six abstracts at the 2025 International Master Course on Aging Science (IMCAS) World Congress highlighting its product portfolio and its contribution to the field of regenerative aesthetics.

“Our new Ultherapy PRIME^® device demonstrates our commitment to persist in innovation,” said Gonzalo Mibelli, EMEA President, Merz Aesthetics. “As one of the leaders in non-invasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform as a proven technology and customizable, long-lasting* treatment option.”

The focus of this year’s Merz Aesthetics Symposium at IMCAS is Regenerative Aesthetics. “Patients are looking for more sustainable ways to address aging with regenerative aesthetic treatments providing both preventive and restorative methods to improve skin health and enhance long-term confidence,” said Dr. Kerstin Olsson, Head of Medical Affairs EMEA at Merz Aesthetics. “By collaborating with experts in aesthetics and aging science, this year’s Congress enables us to showcase our advancements and leadership in this field.”

Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.

Merz Aesthetics Symposium RegenX: Elevating Skin, Lifting Confidence. – Dr. Joyce Lim, Dr. Julia Sevi, Dr. Tatjana Pavicic, Dr. Omar Haroon, Dr. Daria Voropai, Saturday, February 1, 10:30 – 12:30
Ultherapy PRIME^® Golden Lounge:
- Opening with Dr. Sabrina Fabi, Thursday, January 30, 12:30
- Expert Roundtable “Non-invasive Regenerative Biostimulation” – Dr. Tatjana Pavicic, Dr. Kerstin Ortlechner, Dr. Sonja Sattler, Thursday, January 30, 14:30
- Expert Roundtable “Importance of Visualization” – Dr. Julia Sevi, Dr. Daria Voropai, Dr. Kerstin Ortlechner, Friday, January 31, 10:00
- Expert Talk “Truly non-invasive Regenerative Collagen Biostimulation” – Dr. Tatjana Pavicic, Dr. Alec McCarthy, Friday, January 31, 12:45
IMCAS Product Analysis Session “HA Skinboosters” – Dr. Mimi Borelli, Global Medical Affairs, Merz Aesthetics, Thursday, January 30, 13:30 – 15:00
IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO, Merz Aesthetics, Friday, January 31, 16:00 – 18:00
IMCAS Product Analysis Session “Aesthetic Toxins: Pipeline & Future” – Andy Curry, PhD, Associate Medical Director, Merz Aesthetics, Saturday, February 1, 14:00 ‒ 15:30

Merz Aesthetics Booth Talks

Connecting with Confidence: Global Insights for a more patient centered approach – Dr. Shannon Humphrey, Thursday, January 30, 14:30
The power of synergy for challenging cases – Dr. Larisa Pfahl, Thursday, January 30, 15:30
Standing out in a competitive marketplace: Building an influential brand in Aesthetics – Dr. Audrey Neff, Friday, January 31, 11:00
2 is better than 1: Optimizing Results – Dr. Chris Hutton, Friday, January 31, 13:00
Synergistic strategies for décolleté treatment in mature patients – Dr. Marie-Eugénie Nichanian-Broglia, Friday, January 31, 13:30
Enhancing Skin Quality: Case study and clinical outcome – Dr. Tatiana Kuznechenkova, Friday, January 31, 15:30

E-Poster Presentations

Virtual posters will be available for viewing on-site throughout the Congress and displayed on the virtual e-poster platform with detailed abstracts.

CaHA microspheres stimulate proteoglycan expression, supporting improved skin quality and elasticity. Authors: Yoana Dimitrova, MSc; Christian Hartmann, PhD; Kristina Riegel, PhD; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl; PhD
Exploring the mode of action of elastin stimulation by CaHA microspheres. Authors: Christian Hartmann, PhD; Kristina Riegel, PhD; Yoana Dimitrova, MSc; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl, PhD
Global Perspectives on Aesthetic Treatments and Approaches for Skin Quality Improvement: Insights from an Expert Advisory Board. Authors: Martina Kerscher, MD; Kate Goldie, MD; Cyro Hirano, MD; Stephen Lowe, MD; Kavita Mariwalla, MD; Milton Moore, MD; Je Young Park, MD; Dusan Sajic, MD; Sonja Sattler, MD; Julieta Spada, MD; Vasanop Vachiramon, MD; Bianca Viscomi, MD
Microfocused Ultrasound in Regenerative Aesthetics: A Narrative Review on Mechanisms of Action and Clinical Outcomes. Authors: Vasanop Vachiramon, MD; Tatjana Pavicic, MD; Gabriela Casabona, MD; Jeremy B. Green, MD; Jennifer Levine, MD; Je Young Park, MD; Julieta Spada, MD; Mariana Muniz, MD; John Akers, PharmD; Matthew Jackson, PhD; Alec McCarthy, PhD
Arterioembolic Characteristics of Hyaluronic Acid and Calcium Hydroxylapatite Fillers within an Artificial Arterial Perfusion Model. Authors: Alec D. McCarthy, PhD; Danny J. Soares, MD; Akash Chandawarkar, MD; Julia Fedorova, MS-I; Yu Zhang, MS-I; Larry Blevins, PA-C; Alexis Bowhay, PA-C; Thomas J. Kean, PhD; David K. Funt, MD
Extracellular Matrix Response to Diluted Calcium Hydroxylapatite Microspheres and Poly-L-Latic Acid Microparticles. Authors: Gabriela Casabona, MD; Kate Goldie, MD; Niamh Corduff, MD; Alec McCarthy, PhD; Korin Leffler, PhD; Thomas Hengl, PhD; Kristina Riegel, PhD

*results can last up to a year or more, Werschler et al. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;(9)2:27-33, Ulthera Instructions For Use.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

Copyright © 2025 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. ULTHERA, ULTHERAPY and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera Inc. in the EU and/or certain other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250123568990/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom